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ABSTRACT 
Background and aims:Lower respiratory infections (LRTIs) are the leading cause of death infectious 
diseases in the world and the fifth leading cause of death in general. The study aimed to identify the general 
characteristics of LRTI, the causative bacteria and the results of sensitivity to antibiotics.  Subjects and 
methods: The study included 555 clinical diagnostic cases as LRTI cases, 328 male and 227 female, aged 3 
to 69 years. Clinical and demographic data were collected in the standard questionnaire, and samples 
included sputum or bronchial lavage (BAL) staining and culture. Samples were cultured in 3 different 
bacterial media, blood agar and LJ slope, chocolate agar with Co2; cultures were then examined for possible 
bacterial pathogens of LRTI. Possible bacterial pathogens were isolated and identified using standard 
laboratory techniques, and microbial sensitivity testing was carried out by disc diffusion method. Results: 
LRTI was recorded among all age groups and with less frequency in children under 16 years of age. A large 
number of LRTI (36.2%) was not diagnosed, most in CAP (52.4%), followed by HAP (33.9%) while 
unidentified cases were lower in AECOPD (22.8%). CAP isolates are K.pneumoniae (26.2%), S.pyogens 
(12.3%), and S.pneumoniae (9%); in HAP are MSSA (24%), E.Coli (12.9%), MRAS (11.1%), 
k.pneumoniae (10.5%) and P.aeruginosa (7%);  and in AECOPD are M.catarrhalis (47.2%), K.pneumoniae 
(17.2%), H.influnzae (10.7%) and P.aeruginosa (2%). In Gram-positive bacteria, high resistance to 
ampicillin/sulbactam (100%) and amoxicillin/clavulanate (100%) was recorded, while moderate resistance 
to amikacin, vancomycin, cefepime and moxifloxacin was recorded. In Gram-negative bacteria, a high 
resistance to 3rd g Cephalosporin’s  (68.5%) was recorded, while a moderate sensitivity to the other 
antibiotics tested was recorded. Conclusions: There is a high rate of undiagnosed LRTI in Yemen and this 
highlights the need for health authorities to develop strategies to diagnose most of the causes of LRTI, 
including Mycoplasma, Chlamydia, and viral causes. No antibiotics are completely effective in treating 
LRTI in our area and antibiotic sensitivity should be performed in all cases. 
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INTRODUCTION 
Lower respiratory tract infection (LRTIs) is the leading cause of infectious diseases of death worldwide, the 
fifth overall cause of death, and the second general cause of disability adjusted life years (DALYs), 
although they are largely preventable causes of diseases and Death1. There have been changes in the 
epidemiology of LRTIs in the past ten years as there has been a decrease in the number of cases among 
children under 5 and an increase in infection among older adults as well as an increase in viral infections1. 
Nevertheless, there is no uniform definition of "LRTIs", a fact which has been said to impede the 
appreciation of its true epidemiological importance2,3. From an epidemiological standpoint, most definitions 
of LRTI include pneumonia, influenza, bronchitis (including acute exacerbations of chronic obstructive 
pulmonary disease [COPD] [AECOPD]) and bronchiolitis as important diseases 1-3.  
   The three major bacterial respiratory pathogens are Streptococcus pneumoniae, Moraxella catarrhalis 
and Haemophilus influenzae. Unfortunately, these causes are spreading and increasing the rate of their 
resistance to antibiotics worldwide4,5,6. The importance of monitoring the progress of this resistance has led 
to many international, regional and national monitoring programs. However, the results of surveillance 
studies show wide differences in sensitivity rates, both geographically and over time7,8. Bacterial resistance 
patterns for antibiotics may differ from one region to another depending on the pressure on the antibiotics 
in that region9. Consequently, there is a great need for local resistance spread data in order to guide the 
experimental prescription and identify areas where new antibiotics with greater effect are needed.  In 
Yemen, data on epidemiology of LRTIs and antibiotic patterns are still rare for bacterial causes. Over the 
past four years, an increase in mortality has been observed among residents of the capital, Sana’a, due to 
LRTIs10. Therefore, the present study was designed to identify the bacterial profile of lower respiratory 
tract infections (LRTIs) in Yemen and to determine the antibiotic susceptibility among these pathogens in 
our areas. 
SUBJECTS AND METHODS 
This study was conducted on 555 hospitalized patients with LRTI in university hospitals in the cities of 
Sana’a and Thamar during the period from October 2015 to October 2018. All patients were subjected to 
full clinical, radiological and relevant laboratory examinations.Clinical sample analyzes were performed in 
the laboratories of the National Center of Public Health laboratories Sana’a (NCPHL)). The study included 
187 patients with community-acquired pneumonia (CAP), 171 patient with hospital-acquired pneumonia 
(HAP) and 197 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)5.  
CAP was defined as acquired pneumonia outside the hospital11. HAP was defined as a pneumonia 
occurring 48 hours or more after admission, which was not developed at the time of admission12. AECOPD 
were defined according to the GOLD guidelines5.  Patient data were collected using questionnaire including 
personal data, clinical symptoms, signs, and history of  preexisting chronic diseases.  Samples included 
sputum or bronchoalveolar lavage (BAL) for staining and culture. Samples were cultured on 3 
bacteriological media. Blood agar aerobically, chocolate agar with Co2 and LJ slope then cultures were 
examined for possible bacterial pathogens of LRTI.  Possible bacterial pathogens were isolated and 
identified using standard laboratory techniques, and microbial sensitivity testing was carried out by means 
of disc diffusion for selected antibiotics. 
RESULTS 
A total of 555 LRTIs hospitalized patients (328/59.1% male and 227/40.9% female) were enrolled in this 
study.  The most frequent age groups were 30-42 years (26.5%), and age group 43-56 years (22.5%); while 
children age group was less frequent (8.5%). Bacterial growth yielded on 354 (63.8%) while 201 (36.2%) 
were negative for bacterial culture (Table 1). A large number of LRTI (36.2%) was not diagnosed, mostly 
in CAP (52.4%), followed by HAP (33.9%) while lower cases were in AECOPD (22.8%). The isolates in 
187 patients with CAP were K.pneumoniae (26.2%), S.pyogens (12.3%), and S.pneumoniae (9%). Isolates 
in 171 patients with HAP were MSSA (24%), E.Coli (12.9%), MRAS (11.1%), K.pneumoniae (10.5%) and 
P.aeruginosa (7%). The organisms in 197 patients with AECOPD were Moraxella catarrhalis (47.2%), 
K.pneumoniae (17.2%), H.influnzae (10.7%) and P.aeruginosa (2%) (Table 2).  Table 3 shows the 
frequency of bacterial causative agents of LRTI; the Subtotal Gram positive bacteria were counted for 
28.3% from total bacteria isolates, while subtotal Gram positive bacteria was counted for  71.7% from the 
total bacterial isolates. The most 3 predominant bacteria isolated from LRTIs patients in the study were  
K.pneumoniae 101(18%),   Moraxella catarrhalis 91(16.8%) and  S.aureus 60 (10.8%), while others 
bacteria such as S.pyogens, S.pneumoniae, H.influnzae, P.aeruginosa, E.coli and Proteus vulgaris were less 
frequent (Table 3). In Gram-positive bacteria high resistance was recorded for ampicillin/sulbactam (100%) 
and amoxicillin/clavulanate  (100%), while a moderate sensitivity rate for amikacin, vancomycin, cefepime 
and moxifloxacin was recorded. In Gram-negative bacteria, a high resistance to 3rd g of cephalosporins 
(68.5%) was recorded, while moderate sensitivity to other tested antibiotics was recorded (Table 4). The 
rates of cure, ICU admission, isolation and death among LRTI cases of positive bacterial growth were 
almost similar to those of negative culture with slight differences. The mortality rate among total LRTIs 
was 25%, while for confirmed LRTI cases in bacterial culture it was 22.9%, which is lower among the 
LRTI cases of negative culture (28.9%) (Table 5). 
DISCUSSION 
   Lower respiratory tract infection (LRTIs) is the leading cause of infectious diseases of death worldwide, 
the fifth general cause of death, and the second general cause of disability adjusted life years (DALYs), 
although they are largely preventable causes of diseases and Death1. In the current study the mortality rate 
among total LRTIs was 25%, while for LRTIs cases confirmed for bacterial culture was 22.9%, lower than 
that among negative culture LRTI cases (28.9%) (Table 5); this rate is higher than that reported by Brown 
and others in the United States of America where the death rate among community-acquired pneumonia 
hospitalizations patients was 7.4%13. While Global Strategy for the Diagnosis, Management and Prevention 
of COPD, reported that long-term prognosis following LRTIs was  poor, with a 5-year mortality of 
approximately 50% 14. The high mortality rate in the current study may be high rates for related factors and 
include comorbidities especially cardiovascular disease, severity of exacerbations, age, previous 
hospitalization, low BMI and malnutrition1. 
  When reviewing the various studies, it is clear that there are some regional differences in the reported 
etiology of LRTIs, as described by Waterer 15. This may be related to a number of factors, but it is also 
important to realize that although LRTIs are not a seasonal disease, many different organisms, including 
S.pneumoniae, influenza virus, Legionella species infections, and even polymicrobial infections do have 
seasonal variations16. In the current study the most 3 predominant bacteria isolated from LRTIs patients  
were  K. pneumoniae 101(18%),   Moraxella catarrhalis 91(16.8%) and  S. aureus 60(10.8%), while 
S.pneumoniae and  H. influnzae were less frequently (Table 3); this result is different from that  
traditionally, the pneumococcus has been reported to be the most common cause of LRTIs17-19 and the 
Global Burden of Disease Study analysis of LRTIs (2015)1 indicated that the pneumococcus was the most 
common cause of LRTIs among all ages. However, our results is go with repots in which there have been 
changes noted in the reported etiology of LRTIs, particularly with the use of more sensitive diagnostic 
tools19-21. In general, it is increasingly recognized that viruses appear to play a bigger role in the etiology of 
LRTIs than has previously been documented22-25 and cases of infection with more than one pathogen, 
commonly the association of one or more viruses with one or more bacterial agents are not uncommon 21,22. 
For patients with CAP, our results (Table 2) showed bacterial profiles similar to those reported by 
international studies6 and regional26. This pattern of "local" hegemony should be taken into account when 
prescribing antimicrobials in our region. When antibiotic sensitivity was considering for bacterial isolates 
from LRTI patients, in Gram positive bacteria a  high resistance was recorded for ampicillin/sulbactam 
(100%) and amoxicillin/clavulanate (100%), while moderate of sensitivity was recorded for amikacin, 
vancomycin, Cefepime and moxifloxacin.  In Gram negative bacteria a  high resistance was recorded for 3rd 
g Cephalosporin’s  (68.5%), while moderate of sensitivity was recorded for other tested antibiotics (Table 
4). Our data revealed high resistance rates for cephalosporins, and the β-lactam-βlactamase inhibitors. 
These findings are in agreement with the increasing prevalence of resistance of Gram positive bacteria as 
S.pneumoniae to those antimicrobial groups, by regional,7,27-29 and worldwide 6,7 studies. Moreover, our 
results highlight the increasing problem of MDR in Gram positive and Gram negative bacteria  of LRTIs, a 
problem that was extensively addressed in the literature28-30.  This warns us of the need for wise use of 
different groups of antimicrobials, especially in our resource-poor country. Moreover, this requires greater 
focus on identifying drivers of resistance relevant and on implementing effective strategies to combat 
resistance and MDR problems. 
   For patients with HAP, the problem of antibiotic resistance seems more important; therefore, the situation 
is more complicated than that in CAP. Nosocomial pneumonias leads to high morbidity and mortality, 
especially among ICU patients8,11. In most clinical cases, there is a need to start empirical antimicrobial 
therapy before obtaining microbial results. However, the situation is further complicated by the emergence 
of several beta-lactamase and MDR pathogens29,31. Obviously there is a great need to obtain data on the 
prevalent strains in HAP; along with the sensitivity pattern to help revise antibiotic policy and guide 
physicians to better manage patients with HAP; especially in developing countries such as Yemen. 
   The current study revealed the present of MRSA, Gram-negative organisms, and P.aeruginosa among 
patients with HAP. This differs clearly from the results obtained by Goel and co-workers31 and even those 
of Ahmed, et al.32, Agmy, et al. 33. Although the later study addressed the problem of HAP in 75 cases of 
ICU patients, the predominant pathogens were S.aureus (32%), P.aeruginosa (30%), and S.pneumoniae 
(15%). It is clear that this "regional" difference explains the changing pattern of pathogens that cause over 
time, even in the same hospital. This underscores the importance of implementing continued local 
monitoring programs8.  Also, our data show an alarming high prevalence of MRSA. This coincides with the 
recent report by Alyahawi, and Al-Safani et al.34,35 who observed that the prevalence of MRSA in invasive 
isolates from hospitals in Yemen  was 23%34.  
CONCLUSION 
Lower respiratory infections are still very common and continue to be a major cause of morbidity and 
mortality in Yemen in children and adults alike, and there are significant changes in the epidemiology of 
LRTIs in terms of their frequency and infectious pathogens. There is a high rate of undiagnosed LRTI in 
Yemen and this highlights the need for health authorities to develop strategies to diagnose most of the 
causes of LRTI, including Mycoplasma, Chlamydia, and viral causes. The most common bacteria in CAP 
in Yemen is K.pneumoniae  while HAP is the S.aureus and Gram negative bacteria. For acute exacerbation 
of COPD, M.catarrahalis was the most common. No antibiotics are completely effective in treating LRTI 
in our area and antibiotic sensitivity should be performed in all cases. 
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Table 1: Distribution of age groups, gender and years among LRTI patients and its correlation with 
bacterial growth outcome. 
 
 
 
 
 
NO 
 
 
% (Total) 
Bacterial growth outcome 
X2 P 
Growth 
 
No growth 
No % No % 
Age category        4.913 0.0296 
(3-16) 47 8.5% 26 55.3%  21 44.7%   
(17-29) 119 21.4% 76 63.8%  43 36.2%   
(30-42) 147 26.5% 92 62.6%  55 37.4%   
(43-56) 125 22.5% 85 68%  40 32%   
≥ 57 117 21.1% 75 64.1%  42 35.9%   
Gender         4.940 0.029 
Male  328 59.1% 218 66.5%  110 33.5%   
Female  227 40.9% 136 60%  86 40%   
Data        19.124 <0.0001 
2015 142 25.6% 90 63.4%  52 35.6%   
2016 178 32.1% 124 69.6%  54 30.4%   
2017 159 28.6% 100 62.9%  59 37.1%   
2018 76 13.7% 40 52.6%  36 47.4%   
Total 555 100.0% 354 63.8%  201 36.2%   
 
Table 2. Bacterial profile of lower respiratory tract infections in Yemen. 
Common Bacterial pathogens (No/%) 
CAP (n=187/33.7%) HAP (n=171/30.8%) AECOPD (n=197/35.5) 
S. pneumoniae (17 /9%)  MRSA (19/11.1 %)  H. influnzae (21/10.7%)  
K. pneumoniae (49 /26.2%) k. pneumoniae (18/10.5%)  K. pneumoniae (34/17.2%) 
St. pyogens (23/12.3%) E. Coli (22/12.9%)  M. catarrhalis (93/47.2%)  
 P. aeruginosa (12/7%)  P. aeruginosa (4/2%) 
 MSSA (41/24%)   
 Proteus vulgaris (1/0.6%)  
No Bacterial growth (98/52.4%) No Bacterial growth (58/33.9%) No Bacterial growth (45/22.8%) 
CAP: Community-acquired pneumonia; HAP: Hospital-acquired pneumonia; AECOPD; Acute exacerbations of chronic obstructive 
pulmonary disease; MRSA: Methecillin-resistant Staphylococcus aureus; MSSA: Methecillin-sensitive Staphylococcus aureus. 
 
 
  
Table 3:  The frequency of bacterial causative agents of LRTI  
 
 
Isolated Bacteria No (%) % Total   n=555 
Gram Positive 
S. pneumoniae 17 (17)  3 
S. aureus 60 (60)  10.8 
S. pyogenes  23 (23)  4.1 
Subtotal Gram positive 100 (28.3) 18 
Gram Negative 
K. pneumoniae 101 (39.8)  18 
H. influenzae 21 (8.3) 3.8 
P. aeruginosa 16 (6.3) 2.9 
Proteus vulgaris 1 (0.4) 0.18 
Moraxella catarrhalis 93 (36.6)  16.8 
E. coli 22 (8.7) 4 
Subtotal Gram negative 254 (71.7) 45.8 
Total positive culture 354  63.8 
Total negative culture 201  36.2 
Fungi 
C. albicans colonization 159  28.6 
 
Table 4: . Antibiotic sensitivity and resistance rates (percentages) of  gram positive and gram negative 
bacteria  in 354 patients with LRTI in Yemen 
Antibiotics Test Bacteria 
Gram positive 
percentage  
Gram negative 
percentage 
Vancomycin S 69.2 ND 
I 11 
R 19.8 
Moxifloxacin S 47.5 71 
I 14 7 
R 38.5 22 
3rd g Cephalosporin’s S 8 22.5 
I 13 9 
R 79 68.5 
Ciprofloxacin S 37 82 
I 12 3.2 
R 51 14.8 
Cefepime S 46 65.4 
I 19 13.1 
R 35 21.5 
* Aampicillin/sulbactam  S 0 48.2 
I 0 11.2 
R 100 40.6 
*Amoxicillin/clavulanate S 0 67 
I 0 11 
R 100 22 
Amikacin S 58.2 80 
I 19 9 
R 22.8 11 
*Not done for P.aeruginosa,  ND= not done 
 
Table 5: The output of LRTI cases  with bacterial infections  in comparison with LRTI cases caused by 
other agents 
Outcome LRTI with bacterial 
infections (n=354) 
LRTI   cases with non-
bacterial agents (n=201) 
Total (n=555) 
No % No % No % 
Cure  273 77.1   143 71.1  416 75 
ICU  22 6.2  31 15.4  53 9.5 
Isolation  1  0.3 3 1.5 4 0.72 
Death   81 22.9 58 28.9 139 25 
Total n=555 354 63.8 201 36.2 555 100 
 
 
 
 
